Haemonetics Corporation — Form 10-Q Summary
Business context and reporting period. Haemonetics provides blood and plasma collection, processing, and management products and software. This report covers the 13-week first quarter of fiscal 2017, ended July 2, 2016, compared with the three months ended June 27, 2015. Fiscal 2017 ends April 1, 2017.
Financial performance and liquidity
| Metric | Quarter ended July 2, 2016 | Prior comparable quarter |
|---|---|---|
| Net revenue | $210.0 million | $213.4 million |
| Gross profit / gross margin | $91.1 million / 43.4% | $102.5 million / 48.0% |
| Operating income (loss) | $(7.9) million | $3.6 million |
| Net income (loss) | $(10.3) million | $(0.3) million |
| Diluted loss per share | $(0.20) | $(0.01) |
| Cash from operating activities | $30.7 million | $9.3 million |
| Capital expenditures | $22.5 million | $24.2 million |
- Revenue declined 1.6% as reported but increased 0.3% excluding foreign-exchange effects. Gross margin fell 460 basis points. Management attributed the pressure to the U.S. blood-filter recall, product mix, blood-center pricing, Japan platelet declines, software impairment, and foreign exchange, partly offset by productivity savings.
- Plasma revenue rose 10.3% and Hemostasis Management rose 9.3%; Blood Center fell 14.6% and Cell Processing fell 6.2%. International revenue declined 9.1%, while U.S. revenue increased 4.1%.
- Cash and cash equivalents were $118.2 million. Working capital was $290.6 million and the current ratio was 2.5. Total debt was approximately $399.7 million based on balance-sheet carrying amounts; management cited $401.0 million of outstanding credit-facility debt. The company reported a net cash position of $281.5 million under its net-debt measure.
- Operating cash flow improved year over year, primarily from working-capital inflows, including higher accrued payroll and restructuring reserves; this improvement may not represent recurring operating performance.
Material changes and management outlook
- Management launched a restructuring program to reduce headcount and operating costs and simplify product lines. It expected approximately $26 million of restructuring and related charges, substantially all cash costs in fiscal 2017, and estimated approximately $40 million of fiscal 2017 savings. The company recorded $17.7 million under the new program in the quarter, plus $1.1 million under a prior program; it estimated about $7 million of savings achieved in the quarter. Further phases could result in additional charges.
- The company expects the American Red Cross agreement and anticipated market-share losses at blood-center group purchasing organizations to reduce fiscal 2017 operating income by approximately $12 million. The Red Cross arrangement is expected to increase share and volume but at lower prices.
- Management reported continued U.S. blood-center collection declines, competitive pricing, and increasing use of double-dose platelet collection in Japan and Europe. It also cited foreign-exchange headwinds, particularly from the Yen and Euro. Full U.S. market release of the TEG 6s device was expected in late fiscal 2017, subject to additional clearance.
Risks, contingencies, and unusual items
- A June 2016 voluntary recall of certain U.S. leukoreduction filters resulted in $3.4 million of charges, including estimated customer returns and inventory reserves. Further customer claims were anticipated but could not yet be estimated; additional charges may be recorded.
- H2 Equity filed a July 2016 arbitration claim seeking $17 million related to the SOLX acquisition. Haemonetics disputes the claim; the company said potential losses could not be reliably estimated and recorded no accrual. Italian employment litigation involved approximately $4.5 million of claimed damages; management considered losses unlikely and recorded no accrual.
- A workforce reduction at a foreign subsidiary affected a previously negotiated tax holiday and led to a $1.4 million discrete tax provision. Unrecognized tax benefits were $3.8 million at quarter-end; the filing describes potential assessments related to historical tax years.
- Disclosure controls were deemed ineffective because a material weakness in income-tax accounting controls had not been fully remediated. Management described remediation steps and said additional procedures were performed for the reported financial statements.
- Foreign-exchange and interest-rate exposure remain relevant. The filing estimated that a 100-basis-point increase in LIBOR would add about $4.0 million to annual interest expense; derivative hedges mitigate but do not eliminate market risk.
Important facts for investors to verify
- Whether recall returns and customer reimbursement claims exceed the $3.4 million recorded provision, and whether insurance provides coverage.
- Whether the restructuring delivers projected savings and whether further phases require additional charges.
- Progress in Blood Center and Cell Processing franchises, including the effects of pricing, market-share changes, and platelet collection trends.
- Resolution and potential financial impact of the SOLX arbitration, Italian litigation, and the foreign tax-holiday assessment.
- Remediation of the income-tax control material weakness and the reliability of future tax reporting.
- Debt repayment, covenant compliance, and the effect of currency and interest-rate changes on earnings and cash flow.